Antithrombotics - Pipeline products to dampen the impact of patent expiries and cost containment initiatives

The ageing of the population will result in an increased incidence of coronary artery disease, heart failure and stroke. In addition to these epidemiological forces, the antithrombotics market will be sustained by the forthcoming launch of innovative novel agents whose sales revenue is expected to dampen the commercial impact of generic incursion in blockbuster proceeds.

Demographic trends lead to an increase in the patient population requiring antithrombotic therapy. However, the rising age of the population across all developed regions is increasing the fiscal burden on healthcare payors which are likely to respond by limiting the reimbursement potential of therapies and put pricing pressure on all agents.

The highest selling brands in the antidiabetics market are Lovenox (enoxaparin) and Plavix (clopidogrel), but these agents are subject to forthcoming genericization and will thus not contribute to the growth of the antithrombotics market in the medium-to-long term. Pipeline agents are expected to become significant drivers in the market.

The antithrombotics market is characterized by pockets of high unmet need and a broad spectrum of similarly efficacious therapeutic strategies. There is regional bias in the choice and popularity of therapeutic strategies driven by cultural reasons as well as infrastructural confines.

Read more...

• Restricted Drug Distribution (02/06/2008)
• Antithrombotics (21/05/2008)
• Antithrombotics (19/05/2008)

• Migraine (27/05/2008)
• Gynecological Cancers (27/05/2008)
• Pricing and Reimbursement in Oncology (27/05/2008)
• Obesity (27/05/2008)
• Therapeutic Cancer Vaccines (27/05/2008)
• Antibacterials (26/05/2008)
• Alzheimer's Disease (26/05/2008)
• Biosimilars: Benchmarking the key players (26/05/2008)
• Atherosclerosis (26/05/2008)

---